Characterization of protease resistance-associated mutations in HIV type 1 drug-naive patients following the increasing prevalence of the CRF02-AG strain in Morocco

AIDS Research and Human Retroviruses

Volumn 28, Issue 6, 2012, Pages 571-577

  Miri, Lamia ^a   Ouladlahsen, Ahd ^b   Kettani, Anass ^c   Bensghir, Rajaa ^b   Marhoum Elfilali, Kamal ^b   Wakrim, Lahcen ^a  

^a Institut Pasteur du Maroc   (Morocco)

^b IBN ROCHD UNIVERSITY HOSPITAL   (Morocco)

^c FACULTÉ DES SCIENCES BEN M SIK   (Morocco)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; TIPRANAVIR;

ADOLESCENT; ADULT; AFRICA; AMINO ACID SUBSTITUTION; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; EUROPE; FEMALE; GENE AMPLIFICATION; GENE CLUSTER; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MOROCCO; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; PHYLOGENY; PREVALENCE; PRIORITY JOURNAL; VIRUS STRAIN; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; ALGORITHMS; DRUG RESISTANCE, VIRAL; FEMALE; HIV PROTEASE INHIBITORS; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; MIDDLE AGED; MOROCCO; MUTATION; PHYLOGENY; PREVALENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 84861846127     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0225     Document Type: Article

References (33)

1. Klimas N, Koneru AÓb, and Fletcher MA: Overview of HIV. Psychosomatic Medicine 2008;70(5):523-530.
2. Taylor BS, Sobieszczyk ME, McCutchan FE, et al.: The challenge of HIV-1 subtype diversity. N Engl J Med 2008;358(15):1590-1602.
3. Buonaguro L, Tornesello ML, and Buonaguro FM: Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: Pathogenetic and therapeutic implications. J Virol 2007;81(19):10209-10219.
4. Hemelaar J, Gouws E, Ghys PD, et al.: Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 2011;25:679-689.
5. Bakhouch K, Oulad-Lahcen A, Bensghir R, et al.: The prevalence of resistance-associated mutations to protease and reverse transcriptase inhibitors in treatment-naïve (HIV1)- infected individuals in Casablanca, Morocco. J Infect Develop Countries 2009;3(05):380.
6. El Annaz H, Recordon-Pinson P, Baba N, et al.: Presence of drug resistance mutations among drug-naive patients in Morocco. AIDS Res Hum Retroviruses 2011;27(8):917-920.
7. Mumtaz G, Hilmi, N, Zidouh A, et al.: HIV modes of transmission analysis in Morocco. Ministry of Health, Department of Epidemiology and Disease Control. 2010. Available at http://www.unaids.org/en/media/unaids/ contentassets/ documents/countryreport/2010/201008- MOT-Morocco-en.pdf.
8. Zolopa AR, Shafer RW, Warford A, et al.: HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med 1999;131(11):813-821.
9. Perno CF, Cozzi-Lepri A, Balotta C, et al.: Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy. J Infect Dis 2001;184(8):983-991.
10. Brenner BG: Resistance and viral subtypes: How important are the differences and why do they occur? Curr Opin HIV AIDS 2007;2(2):94-102.
11. Kantor R: Impact of HIV-1 pol diversity on drug resistance and its clinical implications. Curr Opin Infect Dis 2006;19(6):594-606.
12. Toni TD, Recordon-Pinson P, Minga A, et al.: Presence of key drug resistance mutations in isolates from untreated patients of Abidjan, Coôte d́Ivoire: ANRS 1257 study. AIDS Res Hum Retroviruses 2003;19(8):713-717.
13. Tamura K, Dudley J, Nei M, et al.: MEGA4: molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol Biol Evol 2007;24(8):1596.
14. Thompson JD, Gibson TJ, Plewniak F, et al.: The CLUSTAL- X windows interface: Flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucl Acids Res 1997;25(24):4876.
15. Johnson VA, Brun-Vézinet F, Clotet B, et al.: Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2009;17:138-145.
16. Gifford RJ, Liu TF, Rhee S-Y, et al.: The calibrated population resistance tool: Standardized genotypic estimation of transmitted HIV-1 drug resistance. Bioinformatics 2009;25(9): 1197-1198.
17. Sungkanuparph S, Sukasem C, Manosuthi W, et al.: Tipranavir resistance associated mutations in protease inhibitornaive patients with HIV-1 subtype A/E infection. J Clin Virol 2008;43(3):284-286.
18. El Aouad R, Diez M, and Cherkaoui I: Impact of immigration on HIV and tuberculosis epidemiology in the Euro- Mediterranean area. Euro surveillance: Bulletin européen sur les maladies transmissibles. Eur Commun Dis Bull 2009;14(15).
19. Elharti E. Alami M, Khattabi H, et al.: Some characteristics of the HIV epidemic in Morocco. East Mediterranean Health J 2002;8:819.
20. De Haas H: Morocco: From Emigration Country to Africás Migration Passage to Europe. 2005. Available from http:// www.migrationinformation.org/ Profiles/display.cfm?ID = 339.
21. Njai HF, Gali Y, Vanham G, et al.: The predominance of human immunodeficiency virus type 1 (HIV-1) circulating recombinant form 02 (CRF02-AG) in West Central Africa may be related to its replicative fitness. Retrovirology 2006;3:40.
22. Ragupathy V, Zhao J, Wood O, et al.: Identification of new, emerging HIV-1 unique recombinant forms and drug resistant viruses circulating in Cameroon. Virol J 2011;8(1):185.
23. Esbjörnsson J, Mild M, Månsson F, et al.: HIV-1 molecular epidemiology in Guinea-Bissau, West Africa: Origin, demography and migrations. PLoS One 2011;6(2):e17025.
24. Imamichi H, Koita O, Dabitao D, et al.: Identification and characterization of CRF02-AG, CRF06-cpx, and CRF09-cpx recombinant subtypes in Mali, West Africa. AIDS Res Hum Retroviruses 2009;25(1):45-55.
25. De Mendoza C, Garrido C, Poveda E, et al.: Changes in drug resistance patterns following the introduction of HIV type 1 non-B subtypes in Spain. AIDS Res Hum Retroviruses 2009;25(10):967-972.
26. Lawrence P, Lutz MF, Saoudin H, et al.: Analysis of polymorphism in the protease and reverse transcriptase genes of HIV type 1 CRF02-AG subtypes from drug-naive patients from Saint-Etienne, France. JAIDS J Acquir Immune Defic Syndr 2006;42(4):396.
27. Holguín A, Paxinos E, Hertogs K, et al.: Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes. J Clin Virol 2004;31(3):215-220.
28. Marcelin A-G, Masquelier B, Descamps D, et al.: Tipranavirritonavir genotypic resistance score in protease inhibitorexperienced patients. Antimicrobial Agents Chemother 2008;52(9):3237-3243.
29. Baxter JD, Schapiro JM, Boucher CAB, et al.: Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J Virol 2006;80(21):10794-10801.
30. Poveda E, De Mendoza C, Parkin N, et al.: Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes. AIDS 2008;22(5):611.
31. Paraskevis D, Magiorkinis E, Katsoulidou A, et al.: Prevalence of resistance-associated mutations in newly diagnosed HIV-1 patients in Greece. Virus Res 2005;112(1-2):115-122.
32. Gazzard BG, Anderson J, Babiker A, et al.: British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008;9(8):563-608.
33. Thompson MA, Aberg JA, Cahn P, et al.: Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304(3):321-333.